On the other hand, in patients harboring EGFR mutations, even patients with poor ECOG-PS experience the benefits of improvement in ECOG-PS and survival extension with the use of EGFR-tyrosine kinase inhibitors16, and hence, several guidelines have recommended administration of these agents in NSCLC patients irrespective of ECOG-PS. Here, EGFR is linked to non-small cell lung carcinoma.